Abstract:Qianru Yu, 1, * Maxin Zhang, 1, * Yuetan Chen, 1, * Xiaolong Chen, 2 Sanyuan Shi, 1 Kang Sun, 1 Ran Ye, 1 Yuan Zheng, 1 Yang Chen, 1 Yuhong Xu, 1, 3 Jinliang Peng 1 1 School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; 2 NanoDrug Platform, Zhejiang California International NanoSystems Institute, Zhejiang University, Hangzhou 310058, People's Republic of China; 3 School of Pharmacy and Chemistry, Dali University, Dali City 671000, People's Republic of China *These authors contributed equally to this work Correspondence: Jinliang Peng School of Pharmacy, Shanghai Jiao Tong University, No. 800, Dongchuan Road, Shanghai 200240, People's Republic of China Tel/Fax +86 21 3420 4739 Email pjl76@sjtu.edu.cn Background: The complex preparation procedures and severe toxicities are two major obstacles facing the wide use of chimeric antigen receptor-modified T (CAR-T) cells in clinical cancer immunotherapy. The nanotechnology-based T cell temporary CAR modification may be a potential approach to solve these problems and make the CAR-T cell-based tumor therapy feasible and broadly applicable. Methods: A series of plasmid DNA-loaded self-assembled nanoparticles (pDNA@SNPs x/y ) prepared from adamantane-grafted polyamidoamine (Ad-PAMAM) dendrimers of different generations (G1 or G5) and cyclodextrin-grafted branched polyethylenimine (CD-PEI) of different molecular weights (800, 2000, or 25,000 Da) were characterized and evaluated. The detailed physicochemical properties, cellular interaction, and cytotoxicity of selected pDNA@SNP G1/800 were systematically investigated. Thereafter, the epidermal growth factor receptor variant III (EGFRvIII) CAR-expression plasmid vector (pEGFRvIII-CAR) was constructed and encapsulated into SNP G1/800 . The resulting pEGFRvIII-CAR@SNP G1/800 was used for Jurkat cell transient transfection, and the EGFRvIII-CAR expressed in transfected cells was measured by flow cytometry and Western blot. Finally, the response of EGFRvIII CAR-positive Jurkat T cell to target tumor cell was evaluated. Results: The pDNA@SNP G1/800 showed the highest efficacy in Jurkat cell gene transfection and exhibited low cytotoxicity. pEGFRvIII-CAR@SNP G1/800 can efficiently deliver pEGFRvIII-CAR into Jurkat T cells, thereby resulting in transient EGFRvIII-CAR expression in transfected cells. EGFRvIII-CAR that is present on the cell membrane enabled Jurkat T cells to recognize and bind specifically with EGFRvIII-positive tumor cells. Conclusion: These results indicated that pEGFRvIII-CAR@SNP G1/800 can effectively achieve T-cell transient CAR modification, thereby demonstrating considerable potential in CAR-T cancer therapy. Keywords: self-assembled nanoparticle, PAMAM dendrimer, polyethylenimine, epidermal growth factor receptor variant III, chimeric antigen receptor, T lymphocyte

Optimized peptide nanofibrils as efficient transduction enhancers for in vitro and ex vivo gene transfer

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles

Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells

Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Non-viral vectors for chimeric antigen receptor immunotherapy

Cationic polymers for non-viral gene delivery to human T cells

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

CAR Gene Delivery by T-cell Targeted Lentiviral Vectors is Enhanced by Rapamycin Induced Reduction of Antiviral Mechanisms

A Novel Phosphoester-Based Cationic Co-Polymer Nanocarrier Delivers Chimeric Antigen Receptor Plasmid and Exhibits Anti-Tumor Effect

Technological and Manufacturing Innovation Drive Improved Access to Engineered T Cell Therapies

Optimized DNA electroporation for primary human T cell engineering

Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells

Generation of Antitumor T Cells for Adoptive Cell Therapy with Artificial Antigen Presenting Cells.

Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy

Optimization of electroporation and other non-viral gene delivery strategies for T cells

Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms